Malaria Journal
Papers 6156
1 page of 616 pages (6,156 results)
#1Punam Amratia (UF: University of Florida)H-Index: 4
#2Paul Psychas (UF: University of Florida)H-Index: 2
Last.Denis Valle (UF: University of Florida)H-Index: 12
view all 8 authors...
Background Bayesian methods have been used to generate country-level and global maps of malaria prevalence. With increasing availability of detailed malaria surveillance data, these methodologies can also be used to identify fine-scale heterogeneity of malaria parasitaemia for operational prevention and control of malaria.
Background The Plasmodium falciparum reticulocyte binding protein homolog 2b (PfRh2b) is an important P. falciparum merozoite ligand that mediates invasion of erythrocytes by interacting with a chymotrypsin-sensitive “receptor Z”. A large deletion polymorphism is found in the c-terminal ectodomain of this protein in many countries around the world, resulting in a truncated, but expressed protein. The varying frequencies by region suggest that there could be region specific immune selection at th...
#1Benjamin Abuaku (College of Health Sciences, Bahrain)H-Index: 4
#2Nancy O. Duah-Quashie (College of Health Sciences, Bahrain)H-Index: 1
Last.Kwadwo A. Koram (College of Health Sciences, Bahrain)H-Index: 38
view all 9 authors...
Background Routine surveillance on the therapeutic efficacy of artemisinin-based combination therapy (ACT) has been ongoing in Ghana since 2005. The sixth round of surveillance was conducted between 2015 and 2017 to determine the therapeutic efficacy of artesunate–amodiaquine (AS–AQ) and artemether–lumefantrine (AL) in 10 sentinel sites across the country.
#1Jaishree Raman (UCT: University of Cape Town)H-Index: 1
#2Elizabeth Allen (UCT: University of Cape Town)H-Index: 8
Last.Karen I. Barnes (UCT: University of Cape Town)H-Index: 33
view all 9 authors...
Background To reduce onward falciparum malaria transmission, the World Health Organization recommends adding single low-dose (SLD) primaquine to artemisinin-based combination treatment in low transmission areas. However, uptake of this recommendation has been relatively slow given concerns about whether individual risks justify potential community benefit. This study was undertaken to generate comprehensive local data on the risk–benefit profile of SLD primaquine deployment in a pre-elimination ...
#1Joseph R. M. Fulakeza (UNIMA: University of Malawi)H-Index: 2
#2Sarah McNitt (MSU: Michigan State University)
Last.Karl B. Seydel (MSU: Michigan State University)H-Index: 25
view all 11 authors...
Current World Health Organization guidelines for conducting anti-malarial drug efficacy clinical trials recommend genotyping Plasmodium falciparum genes msp1 and msp2 to distinguish recrudescence from reinfection. A more recently developed potential alternative to this method is a molecular genotyping assay based on a panel of 24 single nucleotide polymorphism (SNP) markers. Performance parameters of these two genotyping methods were compared using data from two recently completed drug efficacy ...
#1Hargobinder KaurH-Index: 4
#2Rakesh SehgalH-Index: 14
Last.Ali A. Sultan (Cornell University)H-Index: 19
view all 9 authors...
Malaria is one of the important vector-borne diseases with high fatality rates in tropical countries. The pattern of emergence and spread of novel antigenic variants, leading to escape of vaccine-induced immunity might be factors responsible for severe malaria. A high level of polymorphism has been reported among malarial antigens which are under selection pressure imposed by host immunity. There are limited reports available on comparative stage-specific genetic diversity among Plasmodium vivax...
#1Maxwell G. Machani (Kenya Medical Research Institute)H-Index: 2
#2Eric Ochomo (Kenya Medical Research Institute)H-Index: 12
Last.Yaw A. Afrane (College of Health Sciences, Bahrain)H-Index: 19
view all 8 authors...
Physiological characteristics (age and blood feeding status) of malaria vectors can influence their susceptibility to the current vector control tools that target their feeding and resting behaviour. To ensure the sustainability of the current and future vector control tools an understanding of how physiological characteristics may contribute to insecticide tolerance in the field is fundamental for shaping resistance management strategies and vector control tools. The aim of this study was to de...
#1Marta F. MaiaH-Index: 11
#2Melissa C. Kapulu (University of Oxford)H-Index: 9
Last.Lisa C. Ranford-Cartwright (Glas.: University of Glasgow)H-Index: 38
view all 8 authors...
Large-scale surveillance of mosquito populations is crucial to assess the intensity of vector-borne disease transmission and the impact of control interventions. However, there is a lack of accurate, cost-effective and high-throughput tools for mass-screening of vectors. A total of 750 Anopheles gambiae (Keele strain) mosquitoes were fed Plasmodium falciparum NF54 gametocytes through standard membrane feeding assay (SMFA) and afterwards maintained in insectary conditions to allow for oocyst (8 d...
#1Jessica de Oliveira Sousa (FIOCRUZ: Oswaldo Cruz Foundation)
Last.Martha Cecilia Suárez-Mutis (FIOCRUZ: Oswaldo Cruz Foundation)H-Index: 11
view all 4 authors...
Background Long-lasting insecticidal nets (LLINs) are one of the main vector control strategies recommended by the World Health Organization for the control and elimination of malaria. This study aimed to evaluate the use and retention of LLINs during the 5 years of implementing an integrated control strategy in a malaria-endemic area in the Brazilian Amazon.
#1Manase Kilonzi (MUHAS: Muhimbili University of Health and Allied Sciences)
#2Omary Minzi (MUHAS: Muhimbili University of Health and Allied Sciences)H-Index: 17
Last.AklilluEleni (Karolinska University Hospital)H-Index: 35
view all 6 authors...
Background In 2006, artemether–lumefantrine (ALU), specifically Coartem® (Novartis Pharma AG, Basel Switzerland), was approved as the first-line drug for treatment of uncomplicated malaria in Tanzania. Due to poor availability and affordability of the innovator’s product, the government of Tanzania in 2013 prequalified the use of generic anti-malarial drugs, whereby Artefan® (Ajanta, Pharma Ltd, India) was the first to be approved.